Calm/Storm Ventures

What they fund

Super-early stage startups, often in their first fundraising round [1]. HealthTech and digital health solutions, including B2B and B2C models [1]. Startups focused on mental health, fertility, chronic conditions, and AI-driven clinical support [1]. Companies with a strong purpose-driven mission and diverse founding teams [1].

Investment thesis

Calm/Storm Ventures invests in purpose-driven founders building digital health solutions to improve human life, health, and wellbeing [1]. The firm targets early-stage HealthTech startups, including digital health, wellbeing, prevention, and care, across B2B and B2C models [1]. They prioritize diversity, with over 50% of their team and portfolio founders from underrepresented groups [1]. The firm aims to create both impact and financial returns, leveraging a founder-centric approach [1].

Credibility: Calm/Storm Ventures' website details their mission, focus areas, and diversity commitment [1].

Value add

Calm/Storm provides strategic guidance, network access, and hands-on involvement [2]. They offer a community of founders supporting founders [1]. Their team includes experienced entrepreneurs and investors [2].

Fit verdict: Ideal for early-stage HealthTech founders seeking a partner with deep industry expertise and a strong network.

Founder diligence script:

• How does Calm/Storm's network specifically support my HealthTech startup's growth?
• What is their typical follow-on investment strategy for early-stage companies?
• How do they measure success beyond financial returns?

Portfolio focus

Mental health (Thymia, Meela, Curio), Fertility and reproductive health (Fertifa, Béa), Chronic conditions and care (Suvera, 9am.health, Univa), AI and clinical decision support (Aeon, Clicks, Leda Health), Digital therapeutics and wellness (Mindstep, The Joy Club, Inne)

Notable investments & exits

Qunomedical was acquired by DocMorris in 2021 [3]. Other exits are not publicly disclosed.

Strategic implications

Calm/Storm's focus on early-stage HealthTech and diversity positions them as a key player in Europe's digital health ecosystem. Their founder-centric approach and hands-on involvement could lead to higher portfolio company success rates. The firm's selective expansion into the US market could enhance its global reach and portfolio diversity.

Where they could go further

Expand focus to include more late-stage HealthTech investments to capture larger exits. Develop a more structured follow-on investment strategy to support portfolio companies through growth stages. Increase transparency around fund size and investment process to attract more LPs.